Polypyrimidine Tract Binding Protein 1 Promotes Lymphatic Metastasis and Proliferation of Bladder Cancer Via Alternative Splicing of MEIS2 and PKM

Ruihui Xie,Xu Chen,Ziyue Chen,Ming Huang,Wen Dong,Peng Gu,Jingtong Zhang,Qianghua Zhou,Wei Dong,Jinli Han,Xisheng Wang,Hui Lie,Jian Huang,Tianxin Lin

DOI: https://doi.org/10.1016/j.canlet.2019.01.041

2018-01-01

SSRN Electronic Journal

Abstract:Lymph node (LN) metastasis is the leading cause of bladder cancer-related mortality. Splicing factors facilitate cancer progression by modulating oncogenic variants, but it is unclear whether and how splicing factors regulate bladder cancer LN metastasis. In this study, Polypyrimidine tract binding protein 1 (PTBP1) expression was found to relate to bladder cancer LN metastasis, and was positively correlated with LN metastasis status, tumor stage, histological grade, and poor patient prognosis. Functional assays demonstrated that PTBP1 promoted bladder cancer cell migration, invasion, and proliferation in vitro, as well as LN metastasis and tumor growth in vivo. Mechanistic investigations revealed that PTBP1 upregulated MEIS2-L variant to promote metastasis and increased expression of PKM2 variant to enhance proliferation by modulating alternative mRNA splicing. Moreover, overexpression of MEIS2-L or PKM2 could rescue the oncogenic abilities of bladder cancer cells and the expression of MMP9 or CCND1 respectively after PTBP1 knockdown. In conclusion, our data demonstrate that PTBP1 induces bladder cancer LN metastasis and proliferation through an alternative splicing mechanism. PTBP1 may serve as a novel prognostic marker and therapeutic target for LN-metastatic bladder cancer.